摘要
非马沙坦是一种新型的非肽类血管紧张素II受体拮抗剂,具有选择性阻滞血管紧张素受体1(AT1)的效果,在多种高血压类型中表现出快速和有效的抗压效果。临床前研究及临床实验表明,非马沙坦耐受性良好,安全性高于其他血管紧张素受体拮抗剂(ARB)类药物,在降低心脏舒张压方面更有效,很有潜力成为未来二十年内最优异的ARB类药物。该药于2010年9月通过韩国食品药品监督管理局批准用于治疗原发性高血压。本文对其药理作用、药动学、临床试验、安全性等进行归纳总结。
Fimasartan is a novel angiotensin Ⅱ receptor antagonist with selectivity for the angiotensin type 1 receptor （AT1） subtype. It shows rapid and effective antihypertensive effects on different types of hypertension. Preclinical and clinical studies show that fimasartan is well tolerated and is more secure than other angiotensin receptor blocker （ARB） drugs, and is more effective in reducing cardiac diastolic blood pressure, so it has the potential to become one of the best ARB drugs in the next twenty years. Fimasartan was approved by Korean Food and Drug Administration for the treatment of essential hypertension in September 2010. The pharmacological action, pharrnacokinetics, clinical trial and safety of fimasartan are reviewed in this paper.
出处
《食品与药品》
CAS
2017年第2期I0003-I0006,共4页
Food and Drug
关键词
非马沙坦
高血压
药理作用
药动学
临床试验
安全性
fimasartan
hypertension
pharmacological action
pharmacokinetics
clinical trial
safety
